Rigosertib produces better OS in MDS than tAML

Print Friendly, PDF & Email


Micrograph showing
myelodysplastic syndrome
Rigosertib has demonstrated activity and tolerability in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia transformed from MDS (tAML), according to researchers. In a phase 1/2 study, rigosertib produced responses in a quarter of MDS/tAML patients and enabled stable disease in another quarter. Overall survival (OS) was about... [Read Article]
Print Friendly, PDF & Email

Generic azacitidine approved in Canada

Print Friendly, PDF & Email


Micrograph showing
acute myeloid leukemia
Health Canada has approved Dr. Reddy’s Laboratories Ltd.’s Azacitidine for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA® (azacitidine for injection). The generic drug is approved for the same indications as VIDAZA®. This includes treating adults with intermediate-2 or high-risk myelodysplastic syndromes (according to the International... [Read Article]
Print Friendly, PDF & Email

ATLG fights GVHD but reduces PFS, OS

Print Friendly, PDF & Email


Micrograph showing GVHD
Image from PLOS ONE
Results of a phase 3 trial suggest rabbit anti-T lymphocyte globulin (ATLG) can reduce graft-versus-host disease (GVHD) but also decrease survival in patients who have received a hematopoietic stem cell transplant (HSCT) from a matched, unrelated donor. In this randomized trial, ATLG significantly decreased the incidence... [Read Article]
Print Friendly, PDF & Email

Mutations impact outcomes in AML, MDS

Print Friendly, PDF & Email


Azacitidine
Photo from Business Wire
Researchers say they have identified genetic mutations that can significantly affect treatment outcomes in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The findings come from a clinical trial in which the team examined whether combining vorinostat with azacitidine could improve survival in patients with AML... [Read Article]
Print Friendly, PDF & Email

FDA grants RMAT designation to HSCT adjunct

Print Friendly, PDF & Email


T cells
Image from NIAID
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ATIR101™, which is intended to be used as an adjunct to haploidentical hematopoietic stem cell transplant (HSCT). ATIR101 is a personalized T-cell immunotherapy—a donor lymphocyte preparation selectively depleted of host-alloreactive T cells through... [Read Article]
Print Friendly, PDF & Email

Antibody shows early promise in AML/MDS trial

Print Friendly, PDF & Email


Micrograph showing MDS
Interim results of a phase 1 study suggest flotetuzumab, a CD123 and CD3 bispecific antibody, may be a feasible treatment option for relapsed or refractory acute myeloid leukemia (AML) or intermediate/high-risk myelodysplastic syndromes (MDS). Researchers said flotetuzumab demonstrated acceptable tolerability in the dose-escalation portion of the study, with infusion-related reactions... [Read Article]
Print Friendly, PDF & Email

VSTs can treat 5 different viral infections after HSCT

Print Friendly, PDF & Email


Ifigeneia Tzannou
(left) and Bilal Omer
Photo from Baylor
College of Medicine
New research suggests virus-specific T cells (VSTs) can protect patients from severe viral infections that sometimes occur after hematopoietic stem cell transplant (HSCT). The VSTs proved effective against 5 different viruses—Epstein-Barr virus (EBV), adenovirus (AdV), cytomegalovirus (CMV), BK virus (BKV), and... [Read Article]
Print Friendly, PDF & Email